• Search History (Register)
  • MeSH Browser
  • [Clear]
    • English

Welcome to the international HTA database


Showing [16381 Records] Selected Records [0 Hits] [Clear]
Year Source Title
2024     NIHR Health Technology Assessment programme Establishing a research partnership to investigate functional loss and rehabilitation towards the end of life
2024     Penn Medicine Center for Evidence-based Practice (CEP) Renal denervation for treatment of resistant hypertension
2024     NIHR Health Services and Delivery Research programme Causes and solutions to workplace psychological ill-health for nurses, midwives and paramedics: the Care Under Pressure 2 realist review
2024     NIHR Health and Social Care Delivery Program Relationship between staff and quality of care in care homes: StaRQ mixed methods study
2024     NIHR Health Technology Assessment programme Bisphosphonate alternative regimens for the prevention of osteoporotic fragility fractures: BLAST-OFF, a mixed-methods study
2024     NIHR Health Technology Assessment programme Evaluation of venous thromboembolism risk assessment models for hospital inpatients: the VTEAM evidence synthesis
2024     HTA Region Stockholm [Comparing coronary computed tomography angiography (CCTA) to exercise electrocardiogram for suspected coronary artery disease: impact on patient outcomes]
2024     National Institute for Health and Care Excellence (NICE) Durvalumab with gemcitabine and cisplatin for treating unresectable or advanced biliary tract cancer. NICE technology appraisal guidance 944
2024     National Institute for Health and Care Excellence (NICE) Treosulfan with fludarabine before allogeneic stem cell transplant for people aged 1 month to 17 years with non-malignant diseases (terminated appraisal). NICE technology appraisal guidance 945
2024     National Institute for Health and Care Excellence (NICE) Olaparib with bevacizumab for maintenance treatment of advanced high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer. NICE technology appraisal guidance 946
2024     National Institute for Health and Care Excellence (NICE) Loncastuximab tesirine for treating relapsed or refractory diffuse large B-cell lymphoma and high-grade B-cell lymphoma after 2 or more systemic treatments. NICE technology appraisal guidance 947
2024     National Institute for Health and Care Excellence (NICE) Ivosidenib for treating advanced cholangiocarcinoma with an IDH1 R132 mutation after 1 or more systemic treatments. NICE technology appraisal guidance 948
2024     National Institute for Health and Care Excellence (NICE) Belumosudil for treating chronic graft-versus-host disease after 2 or more systemic treatments in people 12 years and over. NICE technology appraisal guidance 949
2024     National Institute for Health and Care Excellence (NICE) Nivolumab–relatlimab for untreated unresectable or metastatic melanoma in people 12 years and over. NICE technology appraisal guidance 950
2024     National Institute for Health and Care Excellence (NICE) Olaparib with abiraterone for untreated hormone-relapsed metastatic prostate cancer. NICE technology appraisal guidance 951
2024     National Institute for Health and Care Excellence (NICE) Talazoparib for treating HER2-negative advanced breast cancer with germline BRCA mutations. NICE technology appraisal guidance 952
2024     National Institute for Health and Care Excellence (NICE) Fluocinolone acetonide intravitreal implant for treating chronic diabetic macular oedema. NICE technology appraisal guidance 953
2024     National Institute for Health and Care Excellence (NICE) Epcoritamab for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic treatments. NICE technology appraisal guidance 954
2024     National Institute for Health and Care Excellence (NICE) Dupilumab for treating moderate to severe prurigo nodularis. NICE technology appraisal guidance 955
2024     National Institute for Health and Care Excellence (NICE) Etrasimod for treating moderately to severely active ulcerative colitis in people aged 16 and over. NICE technology appraisal guidance 956
2024     National Institute for Health and Care Excellence (NICE) Momelotinib for treating myelofibrosis-related splenomegaly or symptoms. NICE technology appraisal guidance 957
2024     National Institute for Health and Care Excellence (NICE) Ritlecitinib for treating severe alopecia areata in people 12 years and over. NICE technology appraisal guidance 958
2024     National Institute for Health and Care Excellence (NICE) Daratumumab in combination for treating newly diagnosed systemic amyloid light-chain amyloidosis. NICE technology appraisal guidance 959
2024     National Institute for Health and Care Excellence (NICE) Satralizumab for preventing relapses in neuromyelitis optica spectrum disorders (terminated appraisal). NICE technology appraisal guidance 960
2024     National Institute for Health and Care Excellence (NICE) Sebelipase alfa for treating lysosomal acid lipase deficiency that is not Wolman disease (terminated appraisal). NICE technology appraisal guidance 961
2024     National Institute for Health and Care Excellence (NICE) Olaparib for maintenance treatment of BRCA mutation-positive advanced ovarian, fallopian tube or peritoneal cancer after response to first-line platinum-based chemotherapy. NICE technology appraisal guidance 962
2024     National Institute for Health and Care Excellence (NICE) Dostarlimab with platinum-based chemotherapy for treating advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency. NICE technology appraisal guidance 963
2024     National Institute for Health and Care Excellence (NICE) Cabozantinib with nivolumab for untreated advanced renal cell carcinoma. NICE technology appraisal guidance 964
2024     National Institute for Health and Care Excellence (NICE) Human alpha1-proteinase inhibitor for treating emphysema (terminated appraisal). NICE technology appraisal guidance 965
2024     Health Information and Quality Authority (HIQA) Health technology assessment of birth cohort testing for hepatitis C: a short report update
2024     Health Information and Quality Authority (HIQA) Review of national rare disease strategies in selected countries
2024     Health Technology Wales (HTW) Liposuction for the treatment of chronic lymphoedema
2024     Finnish Coordinating Center for Health Technology Assessment (FinCCHTA) StellarQ-platform (user interface for professionals)
2024     Ontario Health Intrathecal drug delivery systems for cancer pain
2024     The Regional Health Technology Assessment Centre (HTA-centrum) Benefits and risks of using laparoscopic ultrasonography versus intraoperative cholangiography during laparoscopic cholecystectomy for gallstone disease
2024     Penn Medicine Center for Evidence-based Practice (CEP) Robot-assisted vs. laparoscopic surgery for cholecystectomy
2024     NIHR Health Technology Assessment programme KardiaMobile 6L for measuring QT interval in people having antipsychotic medication to inform early value assessment: a systematic review
2024     NIHR Health Technology Assessment programme Allopurinol and cardiovascular outcomes in patients with ischaemic heart disease: the ALL-HEART RCT and economic evaluation
2024     NIHR Health Technology Assessment programme Patient-reported outcome measures for monitoring primary care patients with depression: the PROMDEP cluster RCT and economic evaluation
2024     NIHR Health Technology Assessment programme Prehospital early warning scores for adults with suspected sepsis: the PHEWS observational cohort and decision-analytic modelling study
2024     NIHR Health Services and Delivery Research programme Reducing health inequalities through general practice: a realist review and action framework
2024     NIHR Health Services and Delivery Research programme Safer and more efficient vital signs monitoring protocols to identify the deteriorating patients in the general hospital ward: an observational study
2024     Canadian Agency for Drugs and Technologies in Health (CADTH) Opioid-sparing effects of IV acetaminophen for patients undergoing surgery
2024     Canadian Agency for Drugs and Technologies in Health (CADTH) Aerosol therapy with inhalers during mechanical ventilation
2024     Canadian Agency for Drugs and Technologies in Health (CADTH) Intra-articular hyaluronic acid for osteoarthritis of the hip, shoulder, and ankle
2024     Canadian Agency for Drugs and Technologies in Health (CADTH) Timing of antibiotic therapy for neisseria gonorrhoeae infection
2024     Canadian Agency for Drugs and Technologies in Health (CADTH) Clinical and instrumental swallowing assessments for dysphagia
2024     Canadian Agency for Drugs and Technologies in Health (CADTH) Ketorolac for renal colic
2024     Canadian Agency for Drugs and Technologies in Health (CADTH) Ketamine for adults with substance use disorders
2024     Canadian Agency for Drugs and Technologies in Health (CADTH) Ketamine for adults with treatment-resistant depression or posttraumatic stress disorder: a 2023 update
2024     NIHR Health Technology Assessment programme Surgical versus non-surgical management of lateral compression type-1 pelvic fracture in adults 60 years and older: the L1FE RCT
2024     NIHR Health Technology Assessment programme Early switch from intravenous to oral antibiotic therapy in patients with cancer who have low-risk neutropenic sepsis: the EASI-SWITCH RCT
2024     NIHR Health Technology Assessment programme Lower urinary tract symptoms in men: the TRIUMPH cluster RCT
2024     NIHR Health Technology Assessment programme A randomised, double blind, placebo-controlled trial of a two-week course of dexamethasone for adult patients with a symptomatic Chronic Subdural Haematoma (Dex-CSDH trial)
2024     NIHR Health Technology Assessment programme Software with artificial intelligence-derived algorithms for analysing CT brain scans in people with a suspected acute stroke: a systematic review and cost-effectiveness analysis
2024     NIHR Health Services and Delivery Research programme Practices of falls risk assessment and prevention in acute hospital settings: a realist investigation
2024     NIHR Health Technology Assessment programme Effectiveness of septoplasty compared to medical management in adults with obstruction associated with a deviated nasal septum: the NAIROS RCT
2024     NIHR Health Technology Assessment programme Thromboprophylaxis during pregnancy and the puerperium: a systematic review and economic evaluation to estimate the value of future research
2024     NIHR Health Technology Assessment programme Use of selective gut decontamination in critically ill children: PICnIC a pilot RCT and mixed-methods study
2024     NIHR Health Services and Delivery Research programme The implications of competing risks and direct treatment disutility in cardiovascular disease and osteoporotic fracture: risk prediction and cost effectiveness analysis
2024     Austrian Institute for Health Technology Assessment (AIHTA) [Biomarkers in Parkinson's Disease]
2024     Austrian Institute for Health Technology Assessment (AIHTA) Role of public contributions to the development of health innovations and its integration in value assessment and pricing/reimbursement decisions
2024     Scottish Health Technologies Group (SHTG) Green theatres
2024     Agency for Care Effectiveness (ACE) Cochlear implants for children with single-sided deafness
2024     Agency for Care Effectiveness (ACE) Wingspan stent system for intracranial atherosclerotic stenosis
2024     Agency for Care Effectiveness (ACE) Polatuzumab vedotin for previously untreated diffuse large B-cell lymphoma
2024     Agency for Care Effectiveness (ACE) Abrocitinib, baricitinib, upadacitinib and dupilumab for treating atopic dermatitis
2024     Agency for Care Effectiveness (ACE) Tafamidis for treating transthyretin amyloid cardiomyopathy
2024     Agency for Care Effectiveness (ACE) Pembrolizumab for the adjuvant treatment of renal cell carcinoma
2024     Agency for Care Effectiveness (ACE) Pembrolizumab for treating high-risk early-stage triple-negative breast cancer
2024     Agency for Care Effectiveness (ACE) Anti-vascular endothelial growth factors for treating diabetic macular oedema and age-related macular degeneration
2024     Agency for Care Effectiveness (ACE) Pembrolizumab for treating persistent, recurrent, or metastatic cervical cancer
2024     Agency for Care Effectiveness (ACE) Olaparib for treating germline BRCA-mutated HER2-negative high-risk early breast cancer
2024     Agency for Care Effectiveness (ACE) PCSK9 inhibitors for treating hypercholesterolaemia
2024     NIHR Health Services and Delivery Research programme ‘Why are we stuck in hospital?’ Barriers to people with learning disabilities/autistic people leaving ‘long-stay’ hospital: a mixed methods study
2024     NIHR Health Technology Assessment programme Clinical outcomes and adverse events of bariatric surgery in adults with severe obesity in Scotland: the SCOTS observational cohort study
2024     NIHR Health Technology Assessment programme Strategies used for childhood chronic functional constipation: the SUCCESS evidence synthesis
2024     NIHR Health Technology Assessment programme Abrocitinib, tralokinumab and upadacitinib for treating moderate-to-severe atopic dermatitis
2024     NIHR Health Technology Assessment programme Development and evaluation of a de-escalation training intervention in adult acute and forensic units: the EDITION systematic review and feasibility trial
2024     NIHR Health Technology Assessment programme Clinical and cost-effectiveness of an adapted intervention for preschoolers with moderate to severe intellectual disabilities displaying behaviours that challenge: the EPICC-ID RCT
2024     NIHR Health Technology Assessment programme Undertaking Studies Within A Trial to evaluate recruitment and retention strategies for randomised controlled trials: lessons learnt from the PROMETHEUS research programme
2024     NIHR Health Services and Delivery Research programme Conceptual framework on barriers and facilitators to implementing perinatal mental health care and treatment for women: the MATRIx evidence synthesis
2024     NIHR Health Services and Delivery Research programme Factors within the clinical encounter that impact upon risk assessment within child and adolescent mental health services: a rapid realist synthesis
2024     NIHR Public Health Research (PHR) programme Support needs of survivors of violence against women in urban India: a prospective analysis of client records
2024     Health Information and Quality Authority (HIQA) Advances in the development of clinical practice guidance - scoping review
2024     Health Information and Quality Authority (HIQA) Health technology assessment of Herpes Zoster (shingles) vaccination
2024     Scottish Health Technologies Group (SHTG) Colon capsule endoscopy
2024     Scottish Health Technologies Group (SHTG) Lung cancer AI
2024     Health Technology Wales (HTW) Intensive family preservation programmes for families in crisis
2024     Health Technology Wales (HTW) Video feedback interventions to improve communication within family relationships and support children at risk
2024     Health Technology Wales (HTW) Low energy contact x-ray brachytherapy (CXB) for the treatment of early stage rectal cancer
2024     Health Technology Wales (HTW) Digital tools for the monitoring and management of wounds
2024     NIHR Health Technology Assessment programme A tailored psychological intervention for anxiety and depression management in people with chronic obstructive pulmonary disease: TANDEM RCT and process evaluation
2024     Swiss Federal Office of Public Health (FOPH) Intra-articular glucocorticoid injections for osteoarthritis of the hip or knee
2024     Swiss Federal Office of Public Health (FOPH) Treatment duration of trastuzumab in early HER2-positive breast cancer
2024     Swiss Federal Office of Public Health (FOPH) CAR-T-cell therapies
2024     Swiss Federal Office of Public Health (FOPH) Tumor treating fields (TTFields) therapy for patients with glioblastoma multiforme
2024     Belgian Health Care Knowledge Centre (KCE) Diagnostic Immunohistochemistry and electron microscopy testing in Belgium
2024     Belgian Health Care Knowledge Centre (KCE) Lung cancer screening in a high-risk population
2024     Belgian Health Care Knowledge Centre (KCE) The use of endothelial cell count in the preoperative evaluation of cataract surgery